Chondrosarcoma Foundation: Fifth International Virtual Dialogue (VIA Zoom),Future Initiatives for the Diagnosis and Treatment of Chondrosarcoma
Chondrosarcoma Foundation: Fifth International Virtual Dialogue (VIA Zoom)
Future Initiatives for the Diagnosis and Treatment of Chondrosarcoma
Date: Wednesday, October 4, 2023 Three Weeks from this coming Wednesday
Time: 7:00PM – 9:00PM (EST / New York)
The event is free, all we need is your e-mail address to send you the Zoom link.
The Chondrosarcoma Foundation, Inc. will host their fifth International Forum / Virtual Dialogue featuring the following prominent experts to address new innovations, findings, and technologies to improve the treatment of Chondrosarcoma.
It is very important that you are aware of your treatment options as well as what innovative treatment will become available through research and clinical trials.
Meet Jonathan Trent, M.D.; Ph.D. : The Role of Medications to Treat Chondrosarcoma
Dr. Jonathan C. Trent earned his MD and PhD in cancer biology from The University of Texas Health Science Center where he also completed a residency in internal medicine. He then completed a fellowship in medical oncology at The University of Texas M. D. Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami, Sylvester Comprehensive Cancer Center, he held an appointment as associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas M. D. Anderson Cancer Center in Houston.
Dr. Trent is currently the Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center. Dr. Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and education about sarcoma. As Associate Director for Clinical Research, his goal is to help Sylvester Faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to cancer patients of South Florida and beyond.
The major focus of his clinical, educational and research efforts are with gastrointestinal stromal tumor (GIST), chondrosarcoma, and other sarcomas. The major efforts of Dr. Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.